During the COVID-19 pandemic several countries have seen a high risk of transmission for health care personnel, with some countries having as many 20-25% of nurses and doctors either infected or showing symptoms of COVID-19. In this prospective cohort study, we will systematically screen all hospital staff in the Capital Region of Denmark for IgM and IgG antibodies against SARS-CoV-2 using a point of care tests and an Elisa kit. Testing will be offered 3 times: In April 2020, Maj 2020 and September 2020. All participants will submit a questionnaire regarding exposures, risk factors and symptoms of COVID-19 in relation to each testing. Follow-up will be through electronic patient records and national registries. We will compare the group of health care personnel with data from a control group of healthy volunteer blood donors from the Danish Blood Donor Study. The aim of the study is to investigate the proportion of hospital staff with SARS-CoV-2 antibodies during the study period compared to a control group representing the Danish population. We will compare the test characteristics of the two methods of testing, a point of care test and Elisa. Further, we will investigate the extent to which prior immunization or infection is protective for future infection with COVID-19.
Study Type
OBSERVATIONAL
Enrollment
44,698
Diagnostic kits for IgM/IgG antibodies to SARS-CoV-2
Elisa-test for IgM and IgG to SARS-CoV-2
Herlev Hospital
Herlev, Capital Region, Denmark
Bispebjerg Hospital
København NV, Capital Region, Denmark
Psykiatrisk Center Ballerup
Ballerup Municipality, Denmark
Psykiatrisk Center København
Copenhagen, Denmark
Rigshospitalet
Copenhagen, Denmark
Psykiatrisk Center Amager
Copenhagen, Denmark
Psykiatrisk Center Stolpegaard
Gentofte Municipality, Denmark
Børne- og Ungdomspsykiatrisk Center
Glostrup Municipality, Denmark
Psykiatrisk Center Glostrup
Glostrup Municipality, Denmark
Nordsjaellands Hospital
Hillerød, Denmark
...and 4 more locations
Positive IgM/IgG tests
Proportion of hospital staff who have a positive IgM/IgG tests for antibodies to SARS-CoV-2 on point of care test and/or Elisa compared to the background population
Time frame: At inclusion
Positive IgM/IgG tests
Proportion of hospital staff who have a positive IgM/IgG tests for antibodies to SARS-CoV-2 on point of care test and/or Elisa compared to the background population
Time frame: 1 month
Positive IgM/IgG tests
Proportion of hospital staff who have a positive IgM/IgG tests for antibodies to SARS-CoV-2 on point of care test and/or Elisa compared to the background population
Time frame: 5 month
Comparison of the point of care test and Elisa
Comparison of the resultat from the point of care test and with results from Elisa
Time frame: At inclusion
Comparison of the point of care test and Elisa
Comparison of the resultat from the point of care test and with results from Elisa
Time frame: 1 months
Comparison of the point of care test and Elisa
Comparison of the resultat from the point of care test and with results from Elisa
Time frame: 5 months
Re-infection rate
Number of patients, who were tested positive for antibodies on an earlier test and later are infected with COVID-19
Time frame: 180 days
Re-infection rate
Number of patients, who were tested positive for antibodies on an earlier test and later are infected with COVID-19
Time frame: 360 days
IgM/IgG positive participants on follow-up test
Proportion of IgM/IgG positive participants with a lasting immune response. This will be the participants who are still positive on follow-up
Time frame: 1 month
IgM/IgG positive participants on follow-up test
Proportion of IgM/IgG positive participants with a lasting immune response. This will be the participants who are still positive on follow-up
Time frame: 5 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.